Autopsy report · NCT00642382

Safety and Effectiveness of Agilus (Hyaluronic Acid) for Ankle Osteoarthritis

“For safety concerns”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 8 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry 8 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Cartiva, Inc.

Sponsor type

Industry

Conditions

OSTEOARTHRITIS

Interventions

Agilus; Normal saline

Participants

17

Sites

19

Countries

United States

Trials that died the same way

• AGN-242428 in the Treatment of Plaque Psoriasis
  “safety reason” (81% match in meaning)
• A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
  “Safety Issues” (75% match in meaning)
• Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)
  “Safety-related” (70% match in meaning)
• Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
  “New Safety Information” (68% match in meaning)
• Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
  “For business reasons” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.